Select Page

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) — Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020, after market close. Following the release, Eyenovia’s Chief Executive Officer and Chief Medical Officer Dr. Sean Ianchulev, Chief Financial Officer John Gandolfo, and Vice President of Commercial Michael Rowe, will host a conference call to review the financial and operating results.
The conference call is scheduled to begin at 4:30 pm ET on Tuesday, November 10, 2020. Participants should dial 877-407-9039 (domestic) or 201-689-8470 (international) with the conference code 13713084. A live webcast of the conference call will also be available on the investor relations page of the Company’s corporate website at www.eyenovia.com.After the live webcast, the event will be archived on Eyenovia’s website for one year.About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, pediatric myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.
Eyenovia Investor Contacts:John Gandolfo
jgandolfo@eyenovia.com
(917) 289-1117
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:Diana Soltesz
Pazanga Health Communications
dsoltesz@pazangahealth.com
(818) 618-5634